Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer. NBCG16, PI: Jon Amund Kyte.


EMIT: Establishment of Molecular profiling for Individual Treatment decisions in Early Breast Cancer. PI: Bjørn Naume.


Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting. PI: Olav Engebråten.


ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer. PI: Jon Amund Kyte.


DGBC NATURAL studien (NBCG21). Delbryst versus ingen bestråling til kvinder ≥ 60 år opereret med brystbevarelse for tidlig brystkræft, et klinisk kontrolleret randomiseret fase III studium.


Breast conserving surgery (BCT) after neoadjuvant therapy for large primary breast cancer (T2-T3) with infavourable tumor-to-breast size ratio(NEO‐BCT‐2). Kun aktuell ved inklusjon i I-BCT studien. PI: Helle Skjerven.


Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. PI: Jürgen Geisler.


OPTIMA (EMIT2). Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Bruk av Prosigna test til adjuvant behandlingsbeslutning. PI: Bjørn Naume.

POSITIVE studien

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer. PI: Anna Sætersdal.

Skagen Trial I

Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. PI: Ingvil Mjaaland.